The
clinical potential of Deprenyl
in neurologic and psychiatric disorders
J Knoll
Journal of Neural Transmission,
Supplement (Austria) 1996, -/48 (85-93)
ABSTRACT
This article reviews the results of clinical studies with Deprenyl in various neurologic
and psychiatric disorders except Parkinson's disease. Promising results could be observed
both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one
study of Tourette's syndrome including attention hyperactivity disorders using an average
dosis of 8.1 mg/day. Controversial results were reported for Alzheimer's disease. On the
one hand significant improvement of cognitive functions was found by various authors. On
the other hand in a more recent study no effect on the progression of the disease could be
observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be
necessary for effective treatment. No positive results were found in amyotrophic lateral
sclerosis and in tardive dyskinesias.
|